Spero therapeutics announces third quarter 2024 operating results and provides a business update

Phase 3 pivot-po trial of tebipenem hbr remains on track to complete enrollment in 2h 2025 reiterate cash runway into mid-2026; q3 2024 ending cash balance of $76.3m cambridge, mass., nov. 14, 2024 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced financial results for the third quarter ended september 30, 2024, and provided a business update.
SPRO Ratings Summary
SPRO Quant Ranking